Business metrics from biopharma companies 2019

This statistic depicts select business metrics among the top 25 biopharmaceutical companies for 2019, by focus status of companies. According to the survey, biopharma companies that were more focused expect a historical revenue growth over the last five years of 14 percent, while among less focused companies expectations are around two percent.

Business metrics for 2019 among the top 25 biopharmaceutical companies, by focus

Characteristic	More focused	Less focused
EBITDA margins (%, 5-year average)	40	28
Historical revenue growth (%, 5-year compound annual growth rate)	14	2
Return on invested capital (%, 5-year average)	14	3
Total shareholder return (%, 5-year average)	99	98
Average valuation (enterprise value to revenue multiple)	5	4.1
Average growth gap (in billion U.S. dollars)	1.8	3.8

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

January 2019

More information

Region

Worldwide

Survey time period

as of January 2019

Number of respondents

25 leading biopharmas

Supplementary notes

Companies were classified as more focused or less focused based on the following criterion: if one therapeutic area contributed more than 50% of a company’s biopharma revenue, it was classified as more focused. If 50% of a company’s biopharma revenues came from two or more therapeutic areas it was classified as less focused.

Citation formats